PMV Pharmaceuticals, Inc., a Redwood City, California-based company focused on the discovery and development of p53 targeted small molecule drugs for the treatment of cancer, completed a $30m Series A financing.
The round was led by OrbiMed, with participation from Osage University Partners and founding investor InterWest Partners. In conjunction with the Series A financing, Peter Thompson, M.D., Orbimed Private Equity Partner, will be joining PMV’s Board of Directors.
The company intends to use the funds to advance its pipeline of p53 focused therapeutics.
Founded by p53 leader Arnold Levine and world-renowned virologist Thomas Shenk, and led by David Mack, Ph.D., President and CEO, PMV Pharmaceuticals is developing p53 and p53 pathway modulators for the treatment of cancer.
The company has Research and Development operations in Doylestown, Pennsylvania.